FDA delays feedback on Novo's Victoza

Novo Nordisk said today that the FDA has delayed feedback on its much-anticipated diabetes drug Victoza (liraglutide) until the fourth quarter of this year. The company had predicted a positive response from the agency by this month. "Novo Nordisk continues the constructive dialog with the FDA regarding the regulatory process for liraglutide," the company said in a statement. Novo said the feedback delay will not impact company's financial results for 2009. The drug received EMEA approval in June and is already being marketed in Europe.

- take a look at Novo's release
- read the Reuters write-up

Related Articles:
Novo Nordisk predicts blockbuster diabetes drug approval
Liraglutide beats older diabetes drug in study
Novo wins European support for liraglutide
Expert panel splits vote on Novo's liraglutide
Novo Nordisk releases more liraglutide data